Keywords: |
adult; controlled study; aged; middle aged; major clinical study; overall survival; clinical trial; neurotoxicity; outcome assessment; letter; progression free survival; hematopoietic stem cell transplantation; central nervous system tumor; central nervous system; central nervous system neoplasms; b cell lymphoma; multicenter study; lymphoma; chimeric antigen receptor; therapy; adoptive immunotherapy; immunotherapy, adoptive; immunocompetent cell; non-hodgkin lymphoma; clinical outcome; diffuse large b cell lymphoma; tocilizumab; humans; human; male; female; secondary central nervous system lymphoma; pulmonary amyloidosis; central nervous system cancer; bruton tyrosine kinase inhibitor; chimeric antigen receptor immunotherapy; receptors, chimeric antigen
|